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Supplementary Fig. 1. Sequence alignments of the subdomain for the swap 1 constructs. a, 
Alignment of the GrsA Phe-A domain with the endA Thr[2] and endC Ser[12] A domains, with the 
subdomain regions highlighted. b, An example sequencing result for the subdomain of mutant F1 









Supplementary Fig. 2. Characterization of 2a produced in this study. a, MS/MS 
fragmentation observed in 2a. b, MS/MS fragmentation of y ions. c, MS/MS fragmentation of b 










F1 (Thr[2]  Ser)


















































































































































































































Supplementary Fig. 3. 1H 1D spectra of 1a (a) and 2a (b) in H2O-D2O-TFA (9:1:0.05, v/v/v), 









   
 
Supplementary Fig. 4. 2D NOESY spectra of 1a (a) and 2a (b) in H2O-D2O-TFA (9:1:0.05, 












Supplementary Fig. 5. Enlarged section of the 1H NMR spectra of 1a and 2a. Comparison of 
the proton spectra revealed the loss of a doublet at 1.39 ppm corresponding to the methyl moiety 



























Supplementary Fig. 6. Enlarged section of the NOESY spectra of 1a and 2a, focusing on the 
NH moiety of residue 2. Comparison of correlations from the NH moiety revealed the loss of a 
methyl signal and the appearance of a new signal at 4.06 ppm corresponding to the methylene 





























































Supplementary Fig. 7. Homologous recombination mediated endA gene knock-out and gene 
complementation. Diagnostic PCR using the indicated primers to determine that endA has been 
replaced by an apramycin resistance cassette (aac(3)IV) in the endA deletion strain (ΔendA) and 
has been complemented in endA complementation strain (permEp::endA). Wild type (WT) and 
plasmid used for endA knock-out (pKOendA) were used as controls. This experiment was 
























3a (Ser[12]  Thr)
Calc’ [M+H]+ Obs’d [M+H]+ Calc’ [M+2H]2+ Obs’d [M+2H]2+ Calc’ [M+3H]3+ Obs’d [M+3H]3+
Parent 790.327 790.326
y17 1095.919 1095.919 731.280 731.277







b14 (-FA, -CONH2, -
H2O)
843.329 843.322
b16 (-FA) 978.887 978.861
b2 294.171 294.170
b1 179.143 179.143











Supplementary Fig. 9. Extracted ion chromatographs from LC-HRMS analysis of extracts 
from S. fungicidicus strains used in this study. No production of enduracidin was observed in 






5 6 7 8 9
Time (min)
1a
1b Wild type 
1a = m/z calc. 785.6550, obs. 785.6545 [M+3H]3+
1b = m/z calc. 790.3269, obs. 790.3267 [M+3H]3+


















Supplementary Fig. 10. LC-HRMS/MS characterization of 4a produced by mutant F3 in 
this study. 
 
4a  (Ser[12] aThr)
Calc’ [M+H]+ Obs’d [M+H]+ Calc’ [M+2H]2+ Obs’d [M+2H]2+ Calc’ [M+3H]3+ Obs’d [M+3H]3+
Parent 790.327 790.326
y17 1095.919 1095.920 730.948 730.950







b14 (-FA, -CONH2, -
H2O)
842.827 842.813







































































































































































































4a  (Ser[12]  aThr)
Calc’ [M+H]+ Obs’d [M+H]+ Calc’ [M+2H]2+ Obs’d [M+2H]2+ Calc’ [M+3H]3+ Obs’d [M+3H]3+
Parent 790.327 790.327
y17 1095.919 1095.919





b16 (-FA) 978.887 978.883
b2 294.171 294.1701
b1 179.144 179.143













Supplementary Fig. 12. LC-HRMS/MS characterization of 4a produced by mutant F5 in 
this study. 
  
4a  (Ser[12]  aThr)
Calc’ [M+H]+ Obs’d [M+H]+ Calc’ [M+2H]2+ Obs’d [M+2H]2+ Calc’ [M+3H]3+ Obs’d [M+3H]3+
Parent 790.327 790.327
y17 1095.919 1095.919







b16 (-FA) 978.887 978.870
b2 294.171 294.170
b1 179.144 179.143



















Calc’ [M+H]+ Obs’d [M+H]+ Calc’ [M+2H]3+ Obs’d [M+2H]3+ Calc’ [M+3H]3+ Obs’d [M+3H]3+
Parent 790.327 790.328
y17 1095.919 1095.919








b1 179.144 179.143 
y17 y16 y13 y11
b1
b2












Calc’ [M+H]+ Obs’d [M+H]+ Calc’ [M+2H]3+ Obs’d [M+2H]3+ Calc’ [M+3H]3+ Obs’d [M+3H]3+
Parent 780.983 780.984
y17 1081.903 1081.904 721.605 721.611



















Supplementary Fig. 15. LC-HRMS/MS characterization of 6a produced by mutant F10 in 
this study. 
6a (Ala[16]  Gly)
Calc’ [M+H]+ Obs’d [M+H]+ Calc’ [M+2H]3+ Obs’d [M+2H]3+ Calc’ [M+3H]3+ Obs’d [M+3H]3+
Parent 780.983 780.984
y17 1081.903 1081.904 721.605 721.602



















Supplementary Fig. 16. Calibration curve of commercial enduracidin a standard, plotted 
based on the peak area of the extracted ion chromatogram of m/z 785.6550 [M+H]+. The 
experiment was performed in triplicate, n=3. Data are presented as mean values +/- 
standard error. Source data are provided with this paper. 


























Supplementary Table 1. Bacterial strains and plasmids used in this study. 
Strain/Plasmid Characteristic(s) Source/ 
Reference 
Actinoplanes sp.  
ATCC 33076 
Wild type strain, Ramoplanin-producing ATCC 
Streptomyces coelicolor 
M145 
Wild type strain, CDA-producing ATCC 
Streptomyces sp. 
DSM 40338 
Wild type strain, Pristinamycin-producing DSMZ 
Pseudomonas syringae 
DSM 10604 
Wild type strain, Syringafactin-producing DSMZ 
Streptomyces griseolus 
NRRL 3739 
Wild type strain, predicted to produce Streptobactin NRRL 
Streptomyces rochei 
NRRL B1559 




Wild type strain, predicted to produce Tyrobetaine NRRL 
Streptomyces fungicidicus 
ATCC 21013 Wild type strain, Enduracidin-producing ATCC 
F1 ATCC 21013 derivative with A domain swapping (Thr[2]  Ser[12]) This study 
ΔendA  ΔendA deletion mutant of ATCC 21013  This study 
ΔendA::endA ΔendA mutant of ATCC 21013 complemented with endA (ΔendA::endA)  This study 
F1a ΔendA mutant of ATCC 21013 complemented with endA with A domain swapping (Thr[2]  Ser[12])  This study 
F2 ATCC 21013 derivative with A domain swapping (Ser[12] Thr[2]) This study 
F3 ATCC 21013 derivative with A domain swapping (Ser[12]  Allo-Thr[5]_ Ramo13) This study 
F4 ATCC 21013 derivative with A domain swapping (Ser[12]  Allo-Thr[8]_ Ramo17) This study 
F5 ATCC 21013 derivative with A domain swapping (Ser[12]  Allo-Thr[12]_ Ramo14) This study 
F6 ATCC 21013 derivative with A domain swapping (Ser[12]  Ala[16]) This study 
F7 ATCC 21013 derivative with A domain swapping (Ser[12]  Ala[16]_ Ramo14) This study 
F8 ATCC 21013 derivative with A domain swapping (Gly[14]  Ala[16]) This study 
F9 ATCC 21013 derivative with A domain swapping (Ala[16]  Gly[14]) This study 
F10 ATCC 21013 derivative with A domain swapping (Ala[16]  Gly[14]_ Ramo14) This study 
F11 ATCC 21013 derivative with A domain swapping (Thr[2]  Ser[1]_CDAPS1) This study 
F12 ATCC 21013 derivative with A domain swapping (Ser[12] Thr[2]_Streptobactin) This study 
F13 ATCC 21013 derivative with A domain swapping (Gly[14]  Ala[4]_Tyrobetaine) This study 
F14 ATCC 21013 derivative with A domain swapping (Ala[16]  Gly[8]_Lipopeptide 8D1-1) This study 
F15 ATCC 21013 derivative with A domain swapping (Ser[12] Thr[1]_Antimycin) This study 
F16 ATCC 21013 derivative with A domain swapping (Ser[12] Allo_Thr[2]_Pristinamycin) This study 
F17 ATCC 21013 derivative with A domain swapping (Ser[12] Allo_Thr[5]_Syringafactin) This study 
Escherichia coli 
DH5α Host for general cloning NEB 
ET12567 (pUZ8002) Donor strain for conjugation between E.coli and Streptomyces (1) 






pDWU5 pBluescript KS+ based vector used for gene inactivation and gene complementation in this study  John Innes 
Centre 
pIJ86 Template for ermE* promoter John Innes 
Centre 
pIJ10700 Template for hygromycin resistance cassette John Innes 
Centre 
pSET152 Integrative vector for gene complementation in this study (3) 
pIJ773 Template for apramycin resistance cassette (2) 
pCRISPomyces-2 E.coli-Streptomyces shuttle vector for gene inactivation in Streptomyces species (4) 
pZY104 
pCRISPomyces-1 derivative for A domain swapping (Thr[2]  Ser[12]) This study 
pZY150 
pCRISPomyces-1 derivative for A domain swapping (Ser[12]  Thr[2]) This study 
pZY152 
pCRISPomyces-1 derivative for A domain swapping (Ser[12]  aThr[5]_ Ramo13) This study 
pZY153 
pCRISPomyces-1 derivative for A domain swapping (Ser[12]  aThr[8]_ Ramo17) This study 
pZY154 pCRISPomyces-1 derivative for A domain swapping (Ser[12]  aThr[12]_ Ramo14) This study 
pZY187 
pCRISPomyces-1 derivative for A domain swapping (Ser[12]  Ala[16]) This study 
pZY188 
pCRISPomyces-1 derivative for A domain swapping (Ser[12]  Ala[16]_ Ramo14) This study 
pZY167 
pCRISPomyces-1 derivative for A domain swapping (Gly[14]  Ala[16]) This study 
pZY163 
pCRISPomyces-1 derivative for A domain swapping (Ala[16]  Gly[14]) This study 
pZY164 
pCRISPomyces-1 derivative for A domain swapping (Ala[16]  Gly[14]_ Ramo14) This study 
WL1 pCRISPomyces-1 derivative for A domain swapping (Thr[2]  Ser[1]_CDAPS1) This study 
WL15 
pCRISPomyces-1 derivative for A domain swapping (Ser[12] Thr[2]_Streptobactin) This study 
KR20 
pCRISPomyces-1 derivative for A domain swapping (Gly[14]  Ala[4]_Tyrobetaine) This study 
AH22 
pCRISPomyces-1 derivative for A domain swapping (Ala[16]  Gly[8]_Lipopeptide 8D1-1) This study 
KR19 
pCRISPomyces-1 derivative for A domain swapping (Ser[12] Thr[1]_Antimycin) This study 
AH11 
pCRISPomyces-1 derivative for A domain swapping (Ser[12] Allo_Thr[2]_SnbC) This study 







Supplementary Table 2.  Bioinformatics information for each swap mutant 
*  Swap via CRISPR-cas9 editing 
†  Swap via gene complementation 
‡ Predicted natural product and gene cluster 
Shaded regions show successful swaps 
 
 








F1 1* Thr[2] 139 Ser[12] 139 92/93 88/89 
F1a 1† Thr[2] 139 Ser[12] 139 92/93 88/89 
F2 2* Ser[12]  139 Thr[2] 139 92/93 88/89 
F3 3* Ser[12] 139 Allo-Thr[5] (Ramo13) 138 65/75 71/75 
F4 4* Ser[12] 139 Allo-Thr[8] (Ramo17) 143 54/63 55/65 
F5 5* Ser[12] 139 Allo-Thr[12] (Ramo14) 138 59/69 65/71 
F6 6* Ser[12] 139 Ala[16] 135 47/60 28/44 
F7 7* Ser[12] 139 Ala[16] (Ramo14) 133 48/61 31/48 
F8 8* Gly[14]  135 Ala[16] 135 75/82 75/83 
F9 9* Ala[16]  135 Gly[14] 135 75/82 75/83 
F10 10* Ala[16] 135 Gly[14] (Ramo14) 134 64/73 64/74 
F11 11* Thr[2] 139 Ser[1] (CDAPS1) 141 46/56 32/40 
F12 12* Ser[12] 139 Thr[2] (Streptobactin)‡ 143 60/70 64/72 
F13 13* Gly[14]  135 Ala[2] (Tyrobetaine)‡ 144 34/45 29/40 
F14 14* Ala[16]  135 Gly[8] (Lipopeptide 8D1-1)‡ 135 53/65 44/59 
F15 15* Ser[12] 139 Thr[1]
 
(Antimycin)‡ 146 58/67 67/73 
F16 16* Ser[12] 139 Thr[2] 
 
(SnbC) 145 59/70 62/73 






















Supplementary Table 3. Key proton chemical shifts (ppm) that identify each residues in 
enduracidin a and its new analogue.  
 Reported-1a*5 This study-1a** This study-2a** 
Residue NH CHα NH CHα NH CHα 
Asp[1] 8.14 4.58 8.43 4.5 8.41 4.57 
Thr[2] 8.55 4.95 8.48 4.9 8.52 (Ser) 5.05 (Ser) 
Hpg[3] 9.56 5.94 9.76 6.06 9.74 6.03 
Orn[4] 8.73 4.05 8.82 3.85 8.83 3.86 
Thr[5] 7.4 4.39 7.59 4.19 7.58 4.20 
Hpg[6] 8.96 6.81 8.82 6.81 8.81 6.81 
Hpg[7] 9.05 5.43 9.10 5.88 9.09 5.97 
Thr[8] - 3.77 7.55 3.8 7.56 3.84 
Cit[9] 7.64 4.18 7.61 4.2 7.63 4.18 
End[10] 7.73 - 7.76 4.8 7.78 4.87 
Hpg[11] 9.38 6.94 9.33 6.94 9.33 6.93 
Ser[12] 9.45 5.04 9.33 5.05 9.38 5.05 
Dpg[13] 8.97 5.72 9.25 5.8 9.24 5.85 
Gly[14] 7.73 3.87 8.82 4.2 8.83 4.15 
End[15] - - 9.10 5.5 9.09 5.52 
Ala[16] 9.68 4.38 9.54 4.44 9.46 4.48 
Hpg[17] 7.94 5.44 7.85 5.5 7.92 5.59 
Side chain - 5.67 - 5.71 - 5.71 
* H2O-DMSO-d6 (4:1, v/v) 























Supplementary Table 4. Yield of enduracidin (1a & 1b) and engineered variants in each 
cultivation flasks as estimated based on the standard curve of commercial enduracidin standard.  
Production of enduracidin (1a & 1b) and engineered variants (a & b) in mg/L   
1 2 3 4 5 6 7 8 9 10 Average Error 
WT 4.14 0.51 3.68 1.16 0.50 0.91 2.86 3.30 0.65 2.45 2.02 ± 0.45 
F1 0.93 2.77 0.49 0.63 2.90 1.78 0.68 2.64 0.45 1.12 1.44 ± 0.32 
F2 0.65 1.54 0.91 0.95 1.31 1.00 1.87 1.21 0.89 0.80 1.11 ± 0.12 
F3 0.35 0.36 0.62 0.42 0.43 0.49 0.41 0.50 0.66 0.85 0.51 ± 0.05 
F4 0.32 0.29 0.33 0.38 0.31 0.27 0.27 0.43 0.40 0.26 0.33 ± 0.02 
F5 0.48 0.66 0.75 0.61 0.39 0.58 0.55 0.53 0.84 1.01 0.64 ± 0.06 
F8 0.24 0.32 0.24 0.28 0.36 0.32 0.38 0.39 0.35 0.39 0.33 ± 0.02 
F9 0.49 0.32 0.43 0.28 0.51 0.38 0.37 0.33 0.59 0.26 0.40 ± 0.03 
F10 14.55* 1.91 1.41 0.89 15.68* 1.70 1.77 2.97 1.62 0.88 1.64 ± 0.22 
WT** 1.32 2.66 2.37 - - - - - - - 2.11 ± 0.41 
F12** 0.31 0.41 0.27 - - - - - - - 0.33 ± 0.04 
F15** 0.46 0.71 1.83 - - - - - - - 1.00 ± 0.42 
F16** 0.38 0.31 0.54 - - - - - - - 0.41 ± 0.07 
F17** 0.87 0.77 0.55 - - - - - - - 0.73 ± 0.09 
* Statistical outlier 






























Supplementary Table 5. Mutations identified via whole genome sequencing 
 




F1 3272110  C deleted Intergenic region 
F2 No mutations  
F7 1696202-
1696204 
 GAG inserted WP_004933182.1 Insertion of Leu into iron chelate uptake 
ABC transporter family permease 
subunit CDS 
2785247 G to A  WP_121546049.1 Pro to leucine change in a helix-turn-
helix domain-containing protein 
(transcriptional regulator) 
6732973  G inserted WP_121547643.1 Change in reading frame of arginine 
deiminase CDS 
F8 2862314 A to G  (1): WP_121546097.1 
(2): N/A 
2 overlapping genes: (1) silent mutation 
in a phosphatase PAP2 family protein 
CDS; (2) Lys to Arg in a hypothetical 
protein 
3299859 T to C  Intergenic region 
3300293 A to G  WP_121546361.1 Phe to Ser, in  a helix-turn-helix 
domain-containing 
protein(transcriptional regulator) 
3318273 G to A  WP_121548461.1 Leu to Phe in a hypothetical protein 
CDS 
3353049 A to G  WP_004930176.1 Asn to Asp in a M23 family 
metallopeptidase CDS 
3374078 A to G  WP_121546404.1 Glu to Gly in a NAD(P)/FAD-
dependent oxidoreductase 
3380245 A to G  WP_004930124.1 Silent mutation in a sigma-70 family 
RNA polymerase sigma factor 
3391478 A to G  WP_163013272.1 Lys to Glu in a transporter CDS 
3432781 A to G  WP_121546444.1 Leu to Pro in a MFS transporter CDS 
3442305 G to A  WP_121546450.1 Arg to Cys in a molecular chaperone 
Hsp90 
3793404 G to A  WP_121546666.1 Ala to Val in a thiol reductant ABC 
exporter subunit CydD 
4550232  T insertion Intergenic region 
4550248  G insertion Intergenic region 
4984294  C deletion WP_004926351.1 Change in reading frame of a PhoH 
family protein 
F9 2442344  G inserted Intergenic region 
2543897 T to C  WP_121545921.1 Tyr to His in a helix-turn-helix domain-
containing protein (transcriptional 
regulator) 
2747858 G to A  WP-163013249.1 Ala to Thr in a alpha/beta hydrolase 
CDS 
4097794  G deleted N/A Hypothetical protein coding sequence 
(will shift reading frame) 




 Deletion of 9 bp 
(TGGACACCA) 
WP_004926852.1 Deletion of 3 amino acids (Asp, Thr, 
Met) in a sucC gene 
5305688 T to C  WP_048459195.1 Start codon of a GntR family 
transcriptional regulator gene changed 
to a Thr 
F10 2442339  G insertion Intergenic region 








Sequences of subdomains for Swaps 12-15 
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